Authorized purpose: Calculation of percent breast density and breast-density group information (BI-RADS A+B fatty versus C+D dense) as adjunctive information for interpreting physicians assessing breast tissue composition; not a diagnostic aid.
Clinical role
Automated breast-density measurement and classification as adjunctive information in mammography review; not diagnosis.
Images and patients
Mammography/DBT · Breast tissue, including fibroglandular tissue and total breast area, assessed for each breast.
Key limitation
Keep in mind: The packet limits input to compatible full-field digital mammography systems and for-presentation 2D digital mammograms. Results are adjunctive information and are not a diagnostic aid; no clinical study was required to demonstrate substantial equivalence.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Calculation of percent breast density and breast-density group information (BI-RADS A+B fatty versus C+D dense) as adjunctive information for interpreting physicians assessing breast tissue composition; not a diagnostic aid.
Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast tissue, including fibroglandular tissue and total breast area, assessed for each breast. Input: For-presentation 2D digital mammograms in RCC, LCC, RMLO, and LMLO views from compatible FFDM systems, including GE Senograph 2000D, GE Senograph DS, GE Senographe Pristina, Hologic Selenia Dimensions, and Hologic Lorad Selenia.
Who uses it?Intended users: Interpreting physicians.
What does the software produce?Output: For each breast: breast area in cm2, fibroglandular-tissue area in cm2, and percent breast density. For each patient: BI-RADS A+B fatty versus C+D dense group information, displayed on a mammography workstation or PACS as a DICOM mammography Structured Report or secondary capture.
What is its most important limitation?Key limitation: The packet limits input to compatible full-field digital mammography systems and for-presentation 2D digital mammograms. Results are adjunctive information and are not a diagnostic aid; no clinical study was required to demonstrate substantial equivalence.
Clinical takeaway. Clinical role: Calculation of percent breast density and breast-density group information (BI-RADS A+B fatty versus C+D dense) as adjunctive information for interpreting physicians assessing breast tissue composition; not a diagnostic aid.
Evidence takeaway. Evidence from the reviewed source record: Non-clinical verification and validation compared ClariSIGMAM density estimates with expert-radiologist reference measurements, assessed reproducibility over time and between breasts, and evaluated binary density classification against a consensus of four expert readers. The reference-standard dataset had n=837; reported endpoints included kappa 0.734 (95% CI 0.688-0.781) and class-specific table percentages of 86.6% for fatty and 87.3% for dense. These are agreement or class-specific classification results, not sensitivity or specificity.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Calculation of percent breast density and breast-density group information (BI-RADS A+B fatty versus C+D dense) as adjunctive information for interpreting physicians assessing breast tissue composition; not a diagnostic aid.
For-presentation 2D digital mammograms in RCC, LCC, RMLO, and LMLO views from compatible FFDM systems, including GE Senograph 2000D, GE Senograph DS, GE Senographe Pristina, Hologic Selenia Dimensions, and Hologic Lorad Selenia.
For each breast: breast area in cm2, fibroglandular-tissue area in cm2, and percent breast density. For each patient: BI-RADS A+B fatty versus C+D dense group information, displayed on a mammography workstation or PACS as a DICOM mammography Structured Report or secondary capture.
Women whose for-presentation 2D digital mammograms come from compatible full field digital mammography systems; the FDA document does not specify a facility type.
Exact FDA submission
Checked 2026-11-14
Packet wording: "ClariSIGMAM software is a standalone software application that automatically analyzes “for presentation” 2D digital mammograms to assess breast tissue composition." … "The software assesses the breast density of women and generates a breast density group information for the patient". Read from the exact FDA decision document on 2026-11-14.
The packet limits input to compatible full-field digital mammography systems and for-presentation 2D digital mammograms. Results are adjunctive information and are not a diagnostic aid; no clinical study was required to demonstrate substantial equivalence.
Non-clinical verification and validation compared ClariSIGMAM density estimates with expert-radiologist reference measurements, assessed reproducibility over time and between breasts, and evaluated binary density classification against a consensus of four expert readers. The reference-standard dataset had n=837; reported endpoints included kappa 0.734 (95% CI 0.688-0.781) and class-specific table percentages of 86.6% for fatty and 87.3% for dense. These are agreement or class-specific classification results, not sensitivity or specificity.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Non-clinical verification and validation compared ClariSIGMAM density estimates with expert-radiologist reference measurements, assessed reproducibility over time and between breasts, and evaluated binary density classification against a consensus of four expert readers. The reference-standard dataset had n=837; reported endpoints included kappa 0.734 (95% CI 0.688-0.781) and class-specific table percentages of 86.6% for fatty and 87.3% for dense. These are agreement or class-specific classification results, not sensitivity or specificity.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
ClariSIGMAM regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K203785
IndependenceIndependence not established
K203785
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K203785. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: For-presentation 2D digital mammograms in RCC, LCC, RMLO, and LMLO views from compatible FFDM systems, including GE Senograph 2000D, GE Senograph DS, GE Senographe Pristina, Hologic Selenia Dimensions, and Hologic Lorad Selenia.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The device receives digital mammograms using standard DICOM communications and automatically transfers the DICOM summary report to a PACS; output may also be displayed as secondary capture on a mammography workstation. Specific local interface compatibility is not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-11-14 ·
Returned objects
Source context, not route validation: For each breast: breast area in cm2, fibroglandular-tissue area in cm2, and percent breast density. For each patient: BI-RADS A+B fatty versus C+D dense group information, displayed on a mammography workstation or PACS as a DICOM mammography Structured Report or secondary capture.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: For each breast: breast area in cm2, fibroglandular-tissue area in cm2, and percent breast density. For each patient: BI-RADS A+B fatty versus C+D dense group information, displayed on a mammography workstation or PACS as a DICOM mammography Structured Report or secondary capture.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The device receives digital mammograms using standard DICOM communications and automatically transfers the DICOM summary report to a PACS; output may also be displayed as secondary capture on a mammography workstation. Specific local interface compatibility is not established.
ACR AI Central provides an exact-submission model card for ClariSIGMAM; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K203785 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission
The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-09 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.
Authorized purpose: BAC processes screening FFDM and DBT mammograms to detect the presence or absence of breast arterial calcifications at study and breast level and localize detected calcifications for qualified interpreting-physician review.
Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.